The ICC allows a diagnosis of AML for patients with bone marrow or peripheral blood (PB) blasts ≥ 10% in addition to one of the following genetic abnormalities: t(15:17), t(8:21) and Inv 16, along with newly added abnormalities such as t(9:11), t(6:9), inv 3, mutated NPM1 and in frame bZIP mutated CEBPA, and less common rearrangements in RARA, MECOM and KMT2A. AML with t(9:22) continues to require 20% blasts or more to distinguish it from accelerated phase CML. This evidence concerns the gene KMT2A and acute myeloid leukemia.